Raludotatug Deruxtecan (R-DXd) is being studied in a trial for people with advanced or metastatic solid tumors, which are cancers that have spread to other parts of the body. This study focuses on tumors with different levels of a protein called cadherin-6 (CDH6). The study includes various cancers like endometrial, cervical, ovarian, bladder, and kidney cancers. The main goal is to see how well the treatment works and how safe it is. **Key Points:** - **Study Duration & Visits:** Participants will need to visit the study site for regular check-ups to monitor their response to the treatment and any side effects. - **Compensation:** Participants may receive compensation for their time and participation in the study. - **Risks:** There might be risks, such as side effects from the treatment, and certain health criteria must be met to participate. This study is important for developing new cancer treatments, but participation requires a commitment to follow the study procedures and eligibility criteria. Participants should discuss with their doctor to see if joining the trial is a good option for them.